Department of Vascular Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Anesthesiology, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.
Department of Vascular Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Angiology and Vascular Surgery, Hospital de Santa Marta, CHLC, Lisbon, Portugal.
J Vasc Surg. 2014 Feb;59(2):275-82. doi: 10.1016/j.jvs.2013.08.029. Epub 2013 Oct 17.
A familial predisposition to abdominal aortic aneurysms (AAAs) is present in approximately one-fifth of patients. Nevertheless, the clinical implications of a positive family history are not known. We investigated the risk of aneurysm-related complications after endovascular aneurysm repair (EVAR) for patients with and without a positive family history of AAA.
Patients treated with EVAR for intact AAAs in the Erasmus University Medical Center between 2000 and 2012 were included in the study. Family history was obtained by written questionnaire. Familial AAA (fAAA) was defined as patients having at least one first-degree relative affected with aortic aneurysm. The remaining patients were considered sporadic AAA. Cardiovascular risk factors, aneurysm morphology (aneurysm neck, aneurysm sac, and iliac measurements), and follow-up were obtained prospectively. The primary end point was complications after EVAR, a composite of endoleaks, need for secondary interventions, aneurysm sac growth, acute limb ischemia, and postimplantation rupture. Secondary end points were specific components of the primary end point (presence of endoleak, need for secondary intervention, and aneurysm sac growth), aneurysm neck growth, and overall survival. Kaplan-Meier estimates for the primary end point were calculated and compared using log-rank (Mantel-Cox) test of equality. A Cox-regression model was used to calculate the independent risk of complications associated with fAAA.
A total of 255 patients were included in the study (88.6% men; age 72 ± 7 years, median follow-up 3.3 years; interquartile range, 2.2-6.1). A total of 51 patients (20.0%) were classified as fAAA. Patients with fAAA were younger (69 vs 72 years; P = .015) and were less likely to have ever smoked (58.8% vs 73.5%; P = .039). Preoperative aneurysm morphology was similar in both groups. Patients with fAAA had significantly more complications after EVAR (35.3% vs 19.1%; P = .013), with a twofold increased risk (adjusted hazard ratio, 2.1; 95% confidence interval, 1.2-3.7). Secondary interventions (39.2% vs 20.1%; P = .004) and aneurysm sac growth (20.8% vs 9.5%; P = .030) were the most important elements accounting for the difference. Furthermore, a trend toward more type I endoleaks during follow-up was observed (15.6% vs 7.4%; P = .063) and no difference in overall survival.
The current study shows that patients with a familial form of AAA develop more aneurysm-related complications after EVAR, despite similar AAA morphology at baseline. These findings suggest that patients with fAAA form a specific subpopulation and create awareness for a possible increase in the risk of complications after EVAR.
大约五分之一的患者存在腹主动脉瘤(AAA)的家族易感性。然而,阳性家族史的临床意义尚不清楚。我们研究了有和没有 AAA 阳性家族史的患者接受血管内动脉瘤修复术(EVAR)后的动脉瘤相关并发症风险。
研究纳入了 2000 年至 2012 年期间在伊拉斯谟大学医学中心接受 EVAR 治疗的完整 AAA 患者。通过书面问卷获得家族史。家族性 AAA(fAAA)定义为至少有一名一级亲属患有主动脉瘤的患者。其余患者被认为是散发性 AAA。前瞻性获得心血管危险因素、动脉瘤形态(瘤颈、瘤囊和髂动脉测量值)和随访情况。主要终点是 EVAR 后的并发症,包括内漏、需要二次干预、瘤囊生长、急性肢体缺血和植入后破裂的复合事件。次要终点是主要终点的特定组成部分(内漏、需要二次干预和瘤囊生长)、瘤颈生长和总生存率。使用对数秩(Mantel-Cox)检验比较 Kaplan-Meier 估计的主要终点。使用 Cox 回归模型计算与 fAAA 相关的并发症的独立风险。
共纳入 255 例患者(88.6%为男性;年龄 72 ± 7 岁,中位随访时间为 3.3 年;四分位间距,2.2-6.1)。共有 51 例(20.0%)患者被归类为 fAAA。fAAA 患者更年轻(69 岁 vs. 72 岁;P =.015),且既往吸烟的可能性较小(58.8% vs. 73.5%;P =.039)。两组患者术前动脉瘤形态相似。fAAA 患者 EVAR 后并发症明显更多(35.3% vs. 19.1%;P =.013),风险增加两倍(调整后的危险比,2.1;95%置信区间,1.2-3.7)。二次干预(39.2% vs. 20.1%;P =.004)和瘤囊生长(20.8% vs. 9.5%;P =.030)是造成差异的最重要因素。此外,在随访期间观察到更倾向于出现 I 型内漏(15.6% vs. 7.4%;P =.063),但总生存率无差异。
本研究表明,尽管基线 AAA 形态相似,但具有家族性 AAA 的患者在接受 EVAR 后会发生更多的动脉瘤相关并发症。这些发现表明,fAAA 患者构成了一个特定的亚群,并引起了对 EVAR 后并发症风险增加的关注。